Anticoagulation and Reversal Agents
- As the direct acting oral anticoagulants (DOACs) have short half-lives, they are able to be continued throughout low bleeding risk procedures, or for high bleeding risk procedures, they may be held 1 to 4 days depending on renal function.
- Idarucizumab (Praxbind) is a new FDA-approved targeted reversal agent to reverse the effects of dabigatran (Pradaxa) in those with life-threatening bleeding or requiring urgent or emergent surgery.
- Andexanet alfa is a modified decoy protein newly FDA approved for reversal of apixaban and rivaroxaban, based on results of the ANNEXA-4 trial.